



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Henriksson et al.                      Art Unit : 1626  
Serial No. : 10/525,640                      Examiner : Joseph R. Kosack  
Filed : February 25, 2005                      Conf. No. : 9646  
Title : 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS  
INHIBITORS OF METALLOPROTEINASE MMP12

**MAIL STOP RCE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form, which were cited by the Office in each of the following two co-pending and commonly owned applications: USSN 10/471,501 (January 12, 2004 filing date) and USSN 10/471,499 (January 12, 2004 filing date). The references were cited in USSN 10/471,501 in an Office Action dated April 5, 2007; and in USSN 10/471,499 in an Office Action dated April 6, 2007. Copies of the two aforementioned Office Actions are also enclosed. In both applications, the references were cited by the Office in connection with a 35 U.S.C. § 112, first paragraph (enablement) rejection of claims directed to methods of treating COPD, rheumatoid arthritis, osteoarthritis, atherosclerosis, periodontal disease, and multiple sclerosis.

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EV828216468US

June 8, 2007  
Date of Deposit

Applicant : Henriksson et al.  
Serial No. : 10/525,640  
Filed : February 25, 2005  
Page : 2 of 2

Attorney's Docket No.: 06275-442US1 / 100604-1P US

No fee is believed due as this Statement is being filed concurrently with a Request for Continued Examination under 37 C.F.R. § 1.114. Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No.: 06275-442US1.


Respectfully submitted,

Date: June 8, 2007

John T. Kendall  
John T. Kendall, Ph.D.  
Reg. No. 50,680

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

21657522.doc

Substitute Form PTO-1449 (Modified)  (37 CFR § 1.998(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-442US1	Application No. 10/525,640
	<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		
	Applicant Henriksson et al.		Filing Date February 25, 2005 Group Art Unit 1626

### U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AF							
	AG							
	AH							

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AI	Aigner, T. et al., "Growth Plate Cartilage as Developmental Model in Osteoarthritis Research – Potentials and Limitations", Current Drug Targets, Vol. 8, No. 2, pp. 377-385, (2007).
	AJ	Fujita, Masaki et al., "The pathogenesis of COPD: Lessons Learned from in vivo Animal Models", Med. Sci Monit., Vol. 13, No. 2, RA19-24, (2007).
	AK	MacFadyen, Robert J., "Can Matrix Metalloproteinase Inhibitors Provide a Realistic Therapy in Cardiovascular Medicine," Current Opinion in Pharmacology, Vol. 7, pp. 171-178, (2007).
	AL	PubMed Abstract (provided in enclosed Office Actions) for: Rifkin, B.R. et al, "Blocking Periodontal Disease Progression by Inhibiting Tissue-Destructive Enzymes: A Potential Therapeutic Role for Tetracyclines and Their Chemically-Modified Analogs", Periodontol, 1993 Aug. 64 (8 Suppl), pp. 819-827.
	AM	Rifkin, B.R. et al, "Blocking Periodontal Disease Progression by Inhibiting Tissue-Destructive Enzymes: A Potential Therapeutic Role for Tetracyclines and Their Chemically-Modified Analogs", Periodontol, 1993 Aug. 64 (8 Suppl), pp. 819-827.
	AN	Wingerchuk, Dean M. et al., "Multiple Sclerosis: Current Pathophysiological Concepts", Biology of Disease", Lab Invest 2001, Vol. 81, pp. 263-281.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	